Africa's largest pharmaceutical company, Aspen Pharmacare Holdings Limited has successfully completed the divestment of its Asia-Pacific (APAC) business, including Australia, New Zealand and other Asia Pacific regions (excluding China) unlocking substantial value for the group with estimated net proceeds of approximately R27 billion ($1.6 billion).
In a SENS announcement released on Friday 29 May, the JSE-listed pharmaceutical giant confirmed that all Conditions Precedent have been fulfilled and the transaction closed on 29 May 2026. The company received the full net cash proceeds, which have already been deployed primarily to reduce Group debt.
The Transaction Consideration remained unchanged at AUD 2,370 million with no adjustments at completion. Through effective foreign currency hedging at better-than-expected rates, Aspen achieved net proceeds of around R27 billion — higher than the approximately R25 billion previously estimated. Transaction costs were contained below 5% of the consideration.
This significant cash inflow has materially strengthened Aspen’s balance sheet and enhanced its financial flexibility, positioning the group for new capital allocation opportunities. Aspen described the sale price as compelling value, demonstrating the substantial worth created within the Group over time. The Board believes the current share price does not fully reflect the intrinsic value of the company’s remaining businesses and their strong growth prospects. The enhanced balance sheet also opens greater scope for potential share buybacks to deliver returns to shareholders.
The transaction was first announced in December 2025 and received shareholder approval earlier this year. This deal marks a major milestone in Aspen’s strategy to unlock sum-of-the-parts value and optimise its portfolio.
Chris Mortimer & Associates acted as Legal Advisers, RMB - Rand Merchant Bank as Financial Adviser, Transaction Sponsor and Corporate Broker
Posts
0 Comments